TheStreet upgraded shares of Covetrus (NASDAQ:CVET – Get Rating) from a d+ rating to a c- rating in a report published on Wednesday morning, TheStreetRatingsTable reports.
Separately, Stifel Nicolaus downgraded Covetrus from a buy rating to a hold rating and set a $22.00 target price for the company. in a report on Monday, June 13th. One investment analyst has rated the stock with a sell rating and five have assigned a hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Hold and an average target price of $21.40.
Get
Covetrus alerts:
Covetrus Stock Down 0.1 %
CVET opened at $20.88 on Wednesday. Covetrus has a fifty-two week low of $13.39 and a fifty-two week high of $21.20. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.08 and a current ratio of 1.88. The company has a market capitalization of $2.93 billion, a P/E ratio of -208.80 and a beta of 1.63. The stock has a fifty day moving average of $20.83 and a 200-day moving average of $19.09.
Covetrus (NASDAQ:CVET – Get Rating) last posted its earnings results on Thursday, August 4th. The company reported $0.20 earnings per share for the quarter, hitting analysts' consensus estimates of $0.20. Covetrus had a positive return on equity of 6.83% and a negative net
margin of 0.28%. The company had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.23 billion. On average, equities analysts expect that Covetrus will post 0.84 EPS for the current year.
Insider Activity at Covetrus
In related news, CEO Benjamin Wolin sold 5,292 shares of the business's stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $20.80, for a total value of $110,073.60. Following the completion of the transaction, the chief executive officer now owns 199,780 shares of the company's stock, valued at $4,155,424. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.40% of the stock is owned by insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Crossmark Global Holdings Inc. acquired a new position in Covetrus in the first quarter valued at about $170,000. Profund Advisors LLC grew its position in Covetrus by 19.6% in the first quarter. Profund Advisors LLC now owns 15,485 shares of the company's stock valued at $260,000 after acquiring an additional 2,543 shares during the last quarter. D. E. Shaw & Co. Inc. grew its position in Covetrus by 87.1% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,028,735 shares of the company's stock valued at $20,544,000 after acquiring an additional 479,008 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new position in Covetrus in the first quarter valued at about $343,000. Finally, Tamarack Advisers LP bought a new position in Covetrus in the first quarter valued at about $2,166,000. Institutional investors and hedge funds own 92.20% of the company's stock.
Covetrus Company Profile
(Get Rating)
Covetrus, Inc, together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers.
Featured Stories
- Get a free copy of the StockNews.com research report on Covetrus (CVET)
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Thor Industries Hammers Out A Bottom
- Declining Profits Challenge the CarMax Value Proposition
- Let Paychex Stock Work Hard For You
Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with MarketBeat.com's FREE daily email newsletter.
